Demographic features, clinical characteristics, and prognostic factors of non-epithelial ovarian tumors at Princess Noorah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia

Balkhy, Atheel; Saleh, Eiman; Jabali, Heyam I; Al-Jifree, Hatim M; Alwazzan, Ahmad

doi:10.15537/smj.2022.43.2.20210433

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the probability of survival of MOGCTs and SCSTs varies noticeably between studies, and there are only a small number of previous investigations that have looked at the time course of survival of these cancers, as well as the influence of stage at diagnosis [3,8,9]. Consistent with our findings, several researchers have suggested that patients with SCSTs have a poor survival rate when compared with MOGCTs [1,3,10]. In our research, PSM was used to adjust the confounders, increasing the robustness of the results [11].…”

Section: Discussionsupporting

confidence: 88%

Clinicopathological Features and Survival Trends of Non-Epithelial Ovarian Cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

Zhang,

2023

Oncol Res Treat

View full text Add to dashboard Cite

Introduction: Owing to its low incidence, there no reliable statistics about prognostication derived from large sample sizes have been reported of malignant ovarian germ cell tumors (MOGCTs) and sex cord-stromal tumors (SCSTs). The present study aimed to investigate the clinicopathological prognostic factors and the survival trends of MOGCTs and SCSTs. Materials and Methods: Patients with MOGCTs and SCSTs were recorded in the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2000 and 2019. Clinical, demographic, and treatment characteristics were compared between groups of MOGCTs and SCSTs. Cox risk regression analysis and Kaplan–Meier survival curves were used to compare overall survival (OS) and cancer-specific survival (CSS), and to assess the prognostic factors. Results: Information of 2506 patients with MOGCTs and 1556 patients with SCSTs was extracted from the SEER database, respectively. Aged <40 years and single were more common in patients with MOGCTs than in those with SCSTs. The vast majority of patients with MOGCTs and SCSTs underwent surgery (98.1% vs. 94.5%; P<0.001) and women with MOGCTs were more likely to receive chemotherapy than women with SCSTs (56.1% vs. 32.2%; P<0.001). For both patients before and after propensity-score matching, the 5-year OS rates of patients with SCSTs were lower than that of patients with MOGCTs (P<0.05). In multivariate Cox regression analysis, both age and surgery were independent predictors of OS in patients with MOGCTs and SCSTs. FIGO staging was an independent predictor of CSS in MOGCT patients. Tumor size and chemotherapy were also independent predictors of CSS in patients with SCSTs. Conclusion: Compared to patients with SCSTs, those with MOGCTs tended to be younger and had a higher OS and CSS. Adjuvant chemotherapy after surgery did not prolong OS and CSS in patients with SCSTs.

show abstract

Section: Discussionsupporting

confidence: 88%

Clinicopathological Features and Survival Trends of Non-Epithelial Ovarian Cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

Zhang,

2023

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Another study also indicated that complete surgical cytoreduction had the best survival benefit in advanced epithelial ovarian cancer patients ( 34 ). Balkhy et al indicated that surgery was the cornerstone of treatment for most stages of non-epithelial ovarian cancers, which might correlate with the prognosis of those patients ( 35 ). A retrospective review showed that ovarian cancer patients receiving intraperitoneal chemotherapy were associated with improved 10-year survival of these patients ( 36 ).…”

Section: Discussionmentioning

confidence: 99%

Prediction for 2-year mortality of metastatic ovarian cancer patients based on surveillance, epidemiology, and end results database

Wang

Xue

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

AimTo establish prediction models for 2-year overall survival of ovarian cancer patients with metastasis.MethodsIn total, 4,929 participants from Surveillance, Epidemiology, and End Results (SEER) database were randomly divided into the training set (n = 3,451) and the testing set (n = 1,478). Univariate and multivariable regression were conducted in the training set to identify predictors for 2-year overall survival of metastatic ovarian cancer patients. The C-index was calculated for assessing the performance of the models. The nomogram for the model was plotted. The prediction value of the model was validated in the testing set. Subgroup analysis were performed concerning surgery and chemotherapy status of patients and the metastatic site of ovarian cancer in the testing set. The calibration curves were plotted and the decision curve analysis (DCA) were conducted.ResultsAt the end of follow-up, 2,587 patients were survived and 2,342 patients were dead within 2 years. The 2-year survival rate was 52.5%. The prediction models were constructed based on predictors including age, radiation, surgery and chemotherapy, CA125, and bone, liver, and lung metastasis. The prediction model for 2-year overall survival of ovarian cancer patients with metastasis showed good predictive ability with the C-index of the model of 0.719 (95% CI: 0.706–0.731) in the training set and 0.718 (95% CI: 0.698–0.737) in the testing set. In terms of patients with bone metastasis, the C-index was 0.740 (95% CI: 0.652–0.828) for predicting the 2-year overall survival of ovarian cancer patients. The C-index was 0.836 (95% CI: 0.694–0.979) in patients with brain metastasis, 0.755 (95% CI: 0.721–0.788) in patients with liver metastasis and 0.725 (95% CI: 0.686–0.764) in those with lung metastasis for predicting the 2-year overall survival of ovarian cancer patients.ConclusionThe models showed good predictive performance for 2-year overall survival of metastatic ovarian cancer patients.

show abstract

Demographic features, clinical characteristics, and prognostic factors of non-epithelial ovarian tumors at Princess Noorah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia

Cited by 2 publications

References 10 publications

Clinicopathological Features and Survival Trends of Non-Epithelial Ovarian Cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

Clinicopathological Features and Survival Trends of Non-Epithelial Ovarian Cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

Prediction for 2-year mortality of metastatic ovarian cancer patients based on surveillance, epidemiology, and end results database

Contact Info

Product

Resources

About